Resources Archive | HUB Organoids

Drug discovery to clinical trials in five years

oncology

CONTENT HIGHLIGHT

Drug discovery to clinical trials in five years

Read our Proof-of-concept study that demonstrates how HUB Organoids can streamline the entire preclinical drug development process, resulting in significant savings in time, cost, and resources.

all
fact sheets
on-demand webinars
info sheets
posters
publications
white papers
case studies
blog

Fact sheets

immuno-oncology

Application of HUB Organoids in immuno-oncology drug development

toxicology

HUB Toxicology Organoid Models

organoid technology

License HUB Organoid Technology

On-demand webinars

organoid screening

Patient in the lab®: downscaling patient-derived organoid screening

René Overmeer, Head of Assay Development and Automation HUB Organoids

organoid screening

Model human disease and identify predictive biomarkers of response

Robert Vries, CEO HUB Organoids

organoid screening

Understanding mechanism of disease and identifying therapeutic interventions with HUB Organoids

Robert Vries, CEO HUB Organoids

Posters

immuno-oncology

Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies

immuno-oncology

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

inflammatory bowel disease

Patient-derived organoids as a relevant tool for preclinical IBD research and drug development

immuno-oncology

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

oncology

Developing a patient-derived bladder cancer organoid biobank suitable for large-scale drug screenings

oncology

Development of a medium-to-high throughput organoid and bacteria co-culture platform for the assessment of host-pathogen interaction

Case studies

oncology

Drug discovery to clinical trials in five years

White papers

oncology

Accelerating oncology drug discovery with HUB Organoids®

HUB's blog

Blog

PDO Screen – Patient-derived Organoids meet Cancer Modeling

Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to...

Blog

The FDA Modernization Act 2.0: A patient-centric paradigm shift in drug development

Explore what the new legislative bill means for the future of organoid technology in drug development The use of animals...

Blog

Challenges in preclinical modeling of cancer immunity

Learn how to select the right model for your immunotherapy development Over the past decade, immunotherapy has revolutionized oncology. From...

Info sheets

immuno-oncology

De-risk your immuno-oncology drug development with HUB Organoids®

biobank

HUB Organoid Biobank

Key publications

infectious disease

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

eLife | July 2021

cystic fibrosis

HUB Organoids

Resources

Drug discovery to clinical trials in five years

Explore our resource portfolio

Fact sheets

Application of HUB Organoids in immuno-oncology drug development

HUB Toxicology Organoid Models

License HUB Organoid Technology

On-demand webinars

Patient in the lab®: downscaling patient-derived organoid screening

Model human disease and identify predictive biomarkers of response

Understanding mechanism of disease and identifying therapeutic interventions with HUB Organoids

Posters

Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

Patient-derived organoids as a relevant tool for preclinical IBD research and drug development

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

Developing a patient-derived bladder cancer organoid biobank suitable for large-scale drug screenings

Development of a medium-to-high throughput organoid and bacteria co-culture platform for the assessment of host-pathogen interaction

Case studies

Drug discovery to clinical trials in five years

White papers

Accelerating oncology drug discovery with HUB Organoids®

HUB's blog

PDO Screen – Patient-derived Organoids meet Cancer Modeling

The FDA Modernization Act 2.0: A patient-centric paradigm shift in drug development

Challenges in preclinical modeling of cancer immunity

Info sheets

De-risk your immuno-oncology drug development with HUB Organoids®

HUB Organoid Biobank

Key publications

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids

Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium

Have any questions?